Budesonide induces complete remission in autoimmune hepatitis

doi:10.3748/wjg.v12.i9.1362

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 9

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3924)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

506

HTML

2957

Figures (1-1)

221

Tables (1-2)

240

Sum=3924

Mar 7, 2006 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (50)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Mar 7, 2006; 12(9): 1362-1366
Published online Mar 7, 2006. doi: 10.3748/wjg.v12.i9.1362

Table 1 Patients' characteristics

Patient (Gender/Age)	Diagnosis	IAHG Score	Autoantibodies (titer)				ALT (<0.85μmol/s.L)		ALP (<2.15μmol/s.L)		HAI		Fibrosis	Therapy	Res-
Patient (Gender/Age)	Diagnosis	IAHG Score	ANA	SMA	ANCA	AMA	ALT (<0.85μmol/s.L)		ALP (<2.15μmol/s.L)		HAI		(Ref. 6)	(wk)	ponse
							pre-	post-	pre-	post-	pre-	post-
							Budesonide		Budesonide		Budesonide
First-line therapy
B.M-L. (F/65)	AIH-PBC	19	1280	-	-	-	15.18	0.22	7.12	1.44	5	3	3	24¹	CR
D.B. (M/26)	AIH	14	320	-	-	-	16.4	0.78	3.19	0.95	7	nd	4	36	CR
D.C. (F/49)	AIH	22	640	-	-	-	1.91	0.89	3.89	3.53	4	nd	5	24	NR/AE
H-S.M. (F/31)	AIH	17	160	80	-	-	4.43	0.6	1.62	0.9	7	nd	2	50	CR
K.M. (F/62)	AIH	14	-	-	-	-	3.45	3.59	7.86	6.29	5	nd	4	12²	NR
L.M. (M/60)	AIH	16	640	640	-	-	4.1	0.35	nd	nd	1	nd	0	82	CR
N.G. (F/64)	AIH-PBC	12	2560	-	-	640	10.73	0.38	7.53	1.63	11	1	0	82	CR
S.T. (M/40)	AIH	12	-	-	>80	-	8.39	0.57	7.84	1.36	1	nd	0	24	CR
T.H. (F/50)	AIH	19	640	160	-	-	3.38	6.77	1.54	1.74	9	nd	3	4²	NR
T.E. (F/49)	AIH-PBC	15	-	640	-	1280	2.27	0.58	4.21	1.61	5	2	5	112	CR
Second-line therapy
B.R. (M/39)	AIH	14	160	-	-	-	4.42	0.6	2.16	0.63	6	2	1	100	CR
B.S. (F/25)	AIH	17	160	-	-	-	16.48	0.41	4.89	1.38	6	1	3	116	CR
D.H. (F/61)	AIH-PBC	14	>2560	-	-	-³	2.37	0.45	11.91	1.24	5	3	4	32	CR
F.C. (F/41)	AIH	17	2560	2560	-	320	10.1	0.55	4.6	0.88	6	nd	2	72	CR
G.W. (M/68)	AIH-PBC	6	-	-	-	-	28.65	0.18	4.1	0.77	3	nd	4	110	CR
K.C. (F/40)	AIH	16	640	160	-	-	10.1	0.68	4.6	1.77	4	nd	1	50	CR
S.H-D. (M/64)	AIH-PSC	11	2560	-	-	-	2.01	0.6	30.13	2.3	4	1	1	80	CR
S.U. (F/41)	AIH-PSC	14	1280	-	-	-	20	0.3	5.1	1.65	6	nd	1	124	CR

CR = complete response; NR = no response; ANA = antinuclear antibodies; SMA = antibodies to smooth muscle; AMA = antimitochondrial antibodies; ANCA = antineutrophil cytoplasmic antibodies; 3 = anti-Sp100 positive; PSC = primary sclerosing cholangitis; PBC = primary biliary cirrhosis; ALT = alanine aminotransferase; ALP = alkaline phosphatase; AE=adverse event; HAI = Hepatitis Activity Index; 1 = the therapy was continued with azathioprine; 2=discontinuation of the therapy because of no response;

Citation: Csepregi A, Röcken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006; 12(9): 1362-1366
URL: https://www.wjgnet.com/1007-9327/full/v12/i9/1362.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i9.1362